Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling.
10.4062/biomolther.2014.109
- Author:
Nicole C STODDARD
1
;
Jerold CHUN
Author Information
1. Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA. jchun@scripps.edu
- Publication Type:Review
- Keywords:
Lysophosphatidic acid receptor;
Pharmacology;
Autotaxin;
Cancer;
Autoimmune disease;
Fibrosis
- MeSH:
Arthritis;
Autoimmune Diseases;
Fibrosis;
Hydrocephalus;
Idiopathic Pulmonary Fibrosis;
Pathology;
Pharmacology;
Receptors, Lysophosphatidic Acid;
Scleroderma, Systemic;
Sensitivity and Specificity
- From:Biomolecules & Therapeutics
2015;23(1):1-11
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lysophosphatidic acid (LPA) is a signaling lipid that binds to six known lysophosphatidic acid receptors (LPARs), named LPA1-LPA6. These receptors initiate signaling cascades relevant to development, maintenance, and healing processes throughout the body. The diversity and specificity of LPA signaling, especially in relation to cancer and autoimmune disorders, makes LPA receptor modulation an attractive target for drug development. Several LPAR-specific analogues and small molecules have been synthesized and are efficacious in attenuating pathology in disease models. To date, at least three compounds have passed phase I and phase II clinical trials for idiopathic pulmonary fibrosis and systemic sclerosis. This review focuses on the promising therapeutic directions emerging in LPA signaling toward ameliorating several diseases, including cancer, fibrosis, arthritis, hydrocephalus, and traumatic injury.
